Review Volume 12, Issue 4 pp 4010—4039

Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment — a meta-analysis of randomized controlled trials

Haoyue Den 1, , Xunhu Dong 2, , Mingliang Chen 2, 3, , Zhongmin Zou 2, ,

  • 1 State Key Laboratory of Trauma, Burns and Combined Injury, Second Department of Research Institute of Surgery, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing 400042, China
  • 2 Department of Chemical Defense, School of Military Preventive Medicine, Third Military Medical University (Army Medical University), Chongqing 400038, China
  • 3 Institute of Pathology and Southwest Cancer Centre, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China

received: July 25, 2019 ; accepted: January 24, 2020 ; published: February 15, 2020 ;

https://doi.org/10.18632/aging.102810
How to Cite

Copyright © 2020 Den et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Probiotics are live microbes that confer health benefits to the host. Preliminary animal evidence supports the potential role of probiotics in ameliorating cognitive health, however, findings from clinical trials in Alzheimer’s disease (AD) or mild cognitive impairment (MCI) subjects are controversial. Thus, a meta-analysis is needed to clarify the efficacy of probiotics on cognition in AD or MCI patients. EMBASE, PubMed, Web of Science and Cochrane library were systematically searched and manually screened for relevant published randomized controlled trials (RCTs). Among the 890 citations identified, 5 studies involving 297 subjects met eligibility. There was a significant improvement in cognition (SMD = 0.37; 95% CI, 0.14, 0.61; P = 0.002; I2 = 24%), while a significant reduction in malondialdehyde (SMD = −0.60; 95% CI, −0.91, −0.28; P = 0.000; I2 = 0.0%) and high-sensitivity C-reactive protein (SMD = −0.57; 95% CI, −0.95, −0.20; P = 0.003; I2 = 0.0%) post-intervention levels between the probiotics and control group. This meta-analysis indicated that probiotics improved cognitive performance in AD or MCI patients, possibly through decreasing levels of inflammatory and oxidative biomarkers. However, current evidence is insufficient, and more reliable evidence from large-scale, long-period, RCT is needed.

Introduction

The incidence of Alzheimer’s disease (AD) is increasing globally and has reached the point of being a costly public health issue [1]. AD, featured by impaired cognition and memory loss, is hidden onset and possesses a long incubation period [2], during which mild cognitive impairment (MCI) constitutes the typical prodromal stage [3]. The World Alzheimer Report 2019 [4] showed that 50 million people are living with dementia worldwide. Remarkably, there will be one new case every 3 seconds, and the number is predicted to be 152 million persons by 2050 [1, 4], resulting in a huge lifestyle and economic burden to both the patients and their families. The total estimated worldwide cost of dementia was US$1 trillion and will rise to US$2 trillion by 2030 [1, 4]. Unfortunately, there is currently no curative treatment for cognitive impairment and dementia [5].

The gut microbiota (GM) consists of a vast bacterial community that resides primarily in the lower gut and lives in a symbiotic relationship with the host [6]. Emerging experimental and clinical evidence has demonstrated the close interconnection between the gastrointestinal tract and the brain, known as the gut-brain axis [7]. Recently, the GM has been found to regulate brain development and behavior via the gut-brain axis, and this has been called the microbiota-gut-brain (MGB) axis [8]. It has been found that dysfunction in behavior and cognition is associated with GM dysbiosis [913]. Activation of gut inflammation has been regarded as a possible pathogenic cofactor in cognitive deterioration and dementia [14, 15]. Moreover, the most distinctive alterations in the GM of AD patients are decreased abundance of anti-inflammatory bacterial species (e.g. Bifidobacterium brevestrain A1) and increased abundance of pro-inflammatory flora phyla (e.g. Firmicutes and Bacteroidetes) [1618]. And restoring GM homeostasis could slow down the progression of AD [18, 19]. Therefore, the GM has been proposed as a key player in the pathogenesis of AD and might be a new potential therapeutic target for the prevention and treatment of AD [20, 21].

Probiotics are live microbes that confer health benefits to the host when administered in adequate amounts, possibly through their anti-inflammatory or anti-oxidative effects [2224]. Recently, some probiotics have been shown to influence the central nervous system (CNS) and behavior via the MGB axis [25]. Moreover, eleven preclinical studies have shown that neither single strains nor multi-strain probiotics were beneficial for improving cognitive function in animal models [26]. These preclinical results have indicated that probiotics might be an effective dietary intervention to ameliorate age-associated cognitive deficits. Nevertheless, findings from available clinical trials focusing on the effects of probiotics in patients with AD or MCI are inconsistent [2731]. Additionally, the previous relevant reviews are focused on the effect of probiotics on neurodegenerative and neurodevelopmental disorders in both animal models and human trials. And they found that probiotics showed efficacy in improving psychiatric disorder-related behaviors including anxiety, depression, autism spectrum disorder, and memory abilities [26, 32]. However, the evidence for the effects of psychobiotics on mental and neurological conditions/disorders remains limited. Further studies of psychobiotics are needed in order to determine their effectiveness and mechanism as treatments for various psychiatric disorders. Accordingly, this meta-analysis was the first to quantitatively examine the potential effect of probiotics on cognitive performance and inflammatory and oxidative biomarkers, which might be related to the underlying mechanisms in AD or MCI subjects.

Results

Literature search and screening

A total of 883 records were obtained after the initial search of the electronic databases, and 7 studies were identified through manual searching of the reference lists of relevant published reviews (for a detailed description of the literature search and results, please see the supplementary materials). Of these, 203 trials were removed as duplicates, and 667 publications were excluded after screening the title and abstract. The remaining 20 articles were scrutinized with a full-text screening, of which 15 were excluded for reasons detailed in the PRISMA flow chart (Figure 1). Then, 5 studies were considered eligible and finally included in the quantitative meta-analysis.

PRISMA flow diagram of the literature search and abstraction process.

Figure 1. PRISMA flow diagram of the literature search and abstraction process.

Study characteristics

As shown in Table 1, the publication years of the five included studies ranged from 2016 to 2019, with an aggregated sample of 297 individuals. All studies were randomized, double-blind and controlled trials. Among which, three studies [2729] recruited subjects diagnosed with AD and another two [30, 31] included MCI adults. Most studies included a higher ratio of women except for two studies (one [30] had a balanced proportion and the other [28] did not report the sex ratio of the recruited subjects).

Table 1. Main characteristics of the included studies.

StudyStudy designParticipantsInterventionOutcome assessmentsMain findings
Sample sizeType (diagnostic criteria)Age (M±SD)Sex ratio (M/F)Type of strainsDuration (weeks)DosageCognitive outcomesInflammatory/ oxidative biomarkers
PROCONPROCON
Elmira Akbari (2016)Randomized, double-blind, controlled trial60AD (NINCDS- ADRDA criteria)77.67 ± 2.6282.00 ± 1.696/246/24Multiple (Lactobacillus acidophilus, Lactobacilluscasei, Bifidobacterium bifidum, Lactobacillus fermentum)128×109 (CFU/ g)MMSETAC GSH MDA hs-CRP NOProbiotic consumption for 12 weeks positively affected cognitive function and some metabolic statuses in the AD patients
Omid Reza Tamtaji (2018)Randomized, double-blind, controlled trial90AD (NINCDS- ADRDA criteria)76.2 ± 8.178.8 ± 10.2Multiple (Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium longum)126×109 (CFU/ day)MMSETAC GSH MDA hs-CRP NOProbiotic and selenium co-supplementation for 12 weeks to patients with AD improved cognitive function and some metabolic profiles.
Azadeh Agahi (2018)Randomized, double-blind, controlled trial48AD (NINCDS- ADRDA criteria)79.70 ± 1.7280.57 ± 1.797/1810/13Multiple (Lactobacillus fermentum, Lactobacillusplantarum, Bifidobacterium lactis Lactobacillus acidophilus,Bifidobacterium bifidum, Bifidobacterium longum)123×109 (CFU/ day)TYMTAC GSH MDA NOCognitive and biochemical indications in the patients with severe AD were insensitive to the probiotic supplementation.
Y. Kobayashi (2019)Randomized, double-blind, controlled trial121Subjective memory complaints (MMSE, 22-27)61.5 ± 6.8361.6 ± 6.3730/3130/30Sole (Bifidobacterium breve A1)12>2.0×1010 (CFU/ day)MMSEhs-CRPNo significant intergroup difference was observed in terms of changes in scores from the baseline scores
44MCI (RBANS <41)Sole (Bifidobacterium breve A1)12>2.0×1010 (CFU/ day)MMSESignificant difference between B. breve A1 and placebo groups in terms of MMSE total score in the subjects with MCI
Yun-Ha Hwang (2019)Multi-center, randomized, double-blind, controlled trial100MCI (DSM-5)68.0 ± 5.1269.2 ± 7.0020/3014/36Sole (Lactobacillus plantarum C29)12>1.0 × 1010 (CFU/ day)VLT ACPT DSTDW2009 can be safely administered to enhance cognitive function in individuals with MCI.
Abbreviations: PRO, probiotics group; CON, control group; CFU, colony-forming units; AD, Alzheimer’s disease; MCI, mild cognitive impairment; NINCDS-ADRDA criteria, National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA); MMSE, Mini-Mental State Examination; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; TAC, total anti-oxidant capacity; GSH, total glutathione; MDA, malondialdehyde; hs-CRP, high-sensitivity C-reactive protein; NO, nitric oxide; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, 5th edition; VLT, verbal learning test; ACPT, auditory continuous performance test; DST, digit span test; DW2009, Lactobacillus plantarum C29-fermented soybean.

The intervention duration of the involved studies was all 12 weeks. Two studies [30, 31] used a sole strain of probiotics, while the other three studies applied multiple strains. The study from Azadeh Agahi et al. [29] had two active probiotics groups which were regarded as one group for the present analysis. All studies used a matched placebo that was indistinguishable from the probiotics in terms of packaging, form, appearance, size, taste, smell, and so forth.

With regard to the main findings, three studies [27, 28, 31] found significant difference in improving cognition between the probiotics and control groups, whereas one study [29] found no significant difference, and another study [30] reported mixed findings. Similarly, the results regarding changes in various inflammatory and oxidative metabolites were inconsistent across studies.

Risk of bias assessment

Although all five included studies were RCT designs, one study [29] failed to provide information on the random sequence generation, and three studies [2830] had no information on allocation concealment procedures. All studies described the blindness of the participants and implementing personnel, whereas only two studies [27, 30] reported the blindness of outcome assessments. No risk of incomplete outcome data was found for any of the recruited studies. Overall, the assessment of bias generally reported a low to moderate risk of bias across all domains. The risks of bias assessment across the recruited studies are summarized in Figure 2.

Summary of risk of bias assessment: judgments of the review authors on each risk of bias item for the included studies (n = 5). One study was rated as “low risk of bias”, and the other four were assessed as “moderate risk of bias.” No study was judged as “high risk of bias”.

Figure 2. Summary of risk of bias assessment: judgments of the review authors on each risk of bias item for the included studies (n = 5). One study was rated as “low risk of bias”, and the other four were assessed as “moderate risk of bias.” No study was judged as “high risk of bias”.

Meta-analysis: Main results

Five studies included 154 subjects in the probiotics group and 143 subjects in the control group. A fixed-effects model was selected for quantitative synthesis. In general, the result of meta-analysis revealed a significant difference between the probiotics and control group regarding improvement in cognition (SMD = 0.37; 95% CI, 0.14, 0.61; P = 0.002; I2= 24%). The forest plot of the meta-analysis is shown in Figure 3.

Forest plot showing the standardized mean difference (SMD) in cognitive enhancement, comparing the probiotics group versus the control group. Weights were assigned according to the number of subjects and SD using STATA 12. A fixed-effects model was applied to the meta-analysis. The sizes of the data markers represent the weight of each study, and the diamond indicates the overall estimated effect.

Figure 3. Forest plot showing the standardized mean difference (SMD) in cognitive enhancement, comparing the probiotics group versus the control group. Weights were assigned according to the number of subjects and SD using STATA 12. A fixed-effects model was applied to the meta-analysis. The sizes of the data markers represent the weight of each study, and the diamond indicates the overall estimated effect.

Meanwhile, fixed-effects models were applied to meta-analyses of malondialdehyde (MDA), high-sensitivity C-reactive protein (hs-CRP), total glutathione (GSH) and nitric oxide (NO) on account of acceptable heterogeneity among studies, while a random-effects model was selected for analysis of total anti-oxidant capacity (TAC). The results showed significant decrease in levels of MDA (SMD = −0.60; 95% CI, −0.91, −0.28; P = 0.000; I2 = 0.0%; n = 3 studies; n = 82 subjects) and hs-CRP (SMD = −0.57; 95% CI, −0.95, −0.20; P = 0.003; I2 = 0.0%, n = 2 studies, n = 57 subjects). And no significant differences were observed in TAC (SMD = 0.04; 95% CI, −0.75, 0.83; P = 0.919; I2 = 83.9%, n = 3 studies; n = 82 subjects), GSH (SMD = 0.04; 95% CI, −0.28, 0.35; P = 0.822; I2 = 44.1%; n = 3 studies; n = 82 subjects), and NO (SMD = −0.16; 95% CI, −0.47, 0.15; P = 0.316; I2 = 4.4%; n = 3 studies; n = 82 subjects) between the probiotics and control group. The forest plots of these meta-analyses are shown in Figure 4.

Forest plot showing the effects in the probiotics group versus the control group on biomarkers of inflammation and oxidative stress. (A) Meta-analysis of the effects of probiotics on total anti-oxidant capacity (TAC). (B) Meta-analysis of the effects of probiotics on total glutathione (GSH). (C) Meta-analysis of the effects of probiotics on malondialdehyde (MDA). (D) Meta-analysis of the effects of probiotics on nitric oxide (NO). (E) Meta-analysis of the effects of probiotics on high-sensitivity C-reactive protein (hs-CRP). Weights were assigned according to the number of subjects and SD using STATA 12. A random-effects model was applied to the meta-analysis of TAC, while other biomarkers used a fixed-effects model. The sizes of data markers represent the weight of each study, and the diamonds indicate the overall estimated effect. SMD, standardized mean difference.

Figure 4. Forest plot showing the effects in the probiotics group versus the control group on biomarkers of inflammation and oxidative stress. (A) Meta-analysis of the effects of probiotics on total anti-oxidant capacity (TAC). (B) Meta-analysis of the effects of probiotics on total glutathione (GSH). (C) Meta-analysis of the effects of probiotics on malondialdehyde (MDA). (D) Meta-analysis of the effects of probiotics on nitric oxide (NO). (E) Meta-analysis of the effects of probiotics on high-sensitivity C-reactive protein (hs-CRP). Weights were assigned according to the number of subjects and SD using STATA 12. A random-effects model was applied to the meta-analysis of TAC, while other biomarkers used a fixed-effects model. The sizes of data markers represent the weight of each study, and the diamonds indicate the overall estimated effect. SMD, standardized mean difference.

Subgroup analyses

A total of three subgroup analyses were conducted, and the results were summarized in Table 2 (for forest plots of the subgroup analyses, please see the supplementary materials). The heterogeneity obviously declined only in the subgroup analysis of “MMSE versus non-MMSE” after stratification by cognitive rating scales. Additionally, the meta-analysis results from the subgroups for disease type (AD versus MCI) and strains of flora (multiple versus sole) were consistent with the overall pooled results, while there was no effect on cognition in the subset of studies with the non-MMSE rating scales (SMD = 0.16; 95% CI: −0.17, 0.50; P = 0.33; I2 = 0.0%).

Table 2. Summary of meta-analysis and subgroup analyses on cognition.

Outcome or SubgroupNo. of trialsParticipantsEstimated EffectTest of heterogeneityP2
P1I2 (%)
1.0 Probiotics versus control group52970.37 (0.14, 0.61)0.26240.002
1.1 Subgroup by type of disease
1.1.1 AD31610.36 (0.05, 0.68)0.1252.20.023
1.1.2 MCI21360.39 (0.04, 0.73)0.306.40.028
1.2 Subgroup by cognitive rating scale
1.2.1 MMSE31570.57 (0.25, 0.89)0.4400.001
1.2.2 Non-MMSE21400.16 (-0.17, 0.50)0.4100.33
1.3 Subgroup by strains of flora
1.3.1 Multiple31610.36 (0.05, 0.68)0.1252.20.023
1.3.2 Sole21360.39 (0.04, 0.73)0.306.40.028
Note: P1 for heterogeneity: P < 0.1 was considered to indicate significant heterogeneity across studies. I2 for heterogeneity: I2 > 50% was considered to indicate significant heterogeneity across studies. P2 for meta-analysis: P < 0.05 was considered to indicate a significant effect of probiotics on cognition by using a fixed-effects model.

Publication bias assessment and sensitivity analysis

We quantitatively assessed the publication bias through Egger's test and Begg's test. The results demonstrated no significant publication bias on cognition (Egger's test: P = 0.54, Begg's test: P = 0.81; see supplementary materials). The sensitivity analysis was performed to test the reliability of the meta-analysis results by omitting studies one by one. Systematically removing each trial did not significantly influence the overall effects of probiotics on cognition (see supplementary materials). Thus, the findings between the probiotics and control groups regarding cognitive enhancement were considered reliable.

Discussion

To the best of our knowledge, this study is the first meta-analysis to elucidate the pronounced beneficial effects of probiotics on improving cognition in individuals with AD or MCI, which might be attributed to the effective decrease in some inflammatory and oxidative related biomarkers (MDA and hs-CRP).

Over the past decades, many studies have focused on effective pharmaceutical strategies to control AD; however, none have yet yielded a satisfying therapy. Recently, it has been demonstrated that modification of lifestyle factors such as dietary patterns plays an important role in alleviating cognitive decline [33]. This indicates that it is imperative to explore potential dietary interventions that may ameliorate age-associated cognitive deficits. Probiotics intervention could be a novel and feasible dietary strategy for managing dementia and other related diseases [34]. Remarkably, our findings provide evidence that relatively low-cost, widely available, and well-tolerated probiotics could be potential candidates for the control or prevention of AD and MCI. However, the specific underlying mechanisms remain unknown.

Although the exact pathogenesis of AD is not completely understood, accumulating evidence suggests that the oxidative stress and inflammatory pathways may play a critical role in the underlying mechanisms of cognitive deficits and AD [35]. Increased neuroinflammation and oxidative stress are frequently observed complications in participants with MCI and AD [3638]. Amyloid-beta peptide (Aβ) oligomers has been considered as the major pathogenic factor associated to AD, which tend to accumulate extracellularly as amyloid deposits [39]. Neuroinflammation in AD is thought to be triggered by Aβ and/or by the substances released by dying neurons, causing microglia activation [40, 41]. Activated microglia triggers the recruitment and proliferation of astrocytes that actively bolster the inflammatory response to extracellular Aβ deposits. This neuroinflammatory component of AD is further characterized by a local cytokine (e.g. TNF-α, IL-1β, IL-6) accumulation mediating acute-phase response, activation of the complement cascade and induction of inflammatory enzyme systems such as inducible nitric oxide synthase (iNOS) and COX-2 [42, 43]. Meanwhile, Aβ is also shown to trigger oxidative stress by increasing ROS production through damage in mitochondrial structure and function [44, 45], or the activation of NADPH oxidase in microglia and astrocytes [46, 47], which in turn promotes further Aβ production, triggering a vicious cycle. All these factors, either alone or in concert, can contribute to neuronal dysfunction and death that occur in AD. Accordingly, huge numbers of potential anti-inflammatory and anti-oxidative agents have been explored to develop effective therapeutic strategies for AD.

GM has been reported to play an important role in the pathogenesis of AD through the MGB axis [21], indicating that restoring GM homeostasis may induce beneficial effects on the progression of AD [48]. Probiotics are live microorganisms intended to provide health benefits, generally by improving or restoring the GM [2224, 49]. Moreover, Athari Nik Azm et al. [50] pointed out that reduction in the number of amyloid plaques, inflammation and oxidative stress were observed in an Alzheimer-probiotics group. Kobayashi et al. [51] also revealed that probiotics administration suppressed hippocampal gene expression of inflammation and oxidative stress related genes in an AD mouse model. These results suggest that probiotics might exert health benefits through their anti- inflammatory and anti-oxidative effects. Herein, we found that some inflammatory and oxidative biomarkers (hs-CRP and MDA) were significantly decreased by probiotics, which might be related to the underlying mechanisms of their beneficial effects in AD or MCI subjects. Meanwhile, some inflammatory and oxidative biomarkers (TAC, GSH, and NO) were not significantly different in the meta-analysis. Apart from diverse interventions conditions, such as strains of flora, total intervention duration, dosage, and so forth, it is worthwhile to infer that inflammatory and oxidative stress pathways are not specific to AD and MCI, but potentially play an important role in various kinds of diseases, especially age-related diseases [11]. Additionally, the inflammatory and oxidative biomarkers enrolled in the current study were only a part of the pathophysiology in AD and MCI patients. Therefore, more comprehensive inflammatory and oxidative metabolites need to be tested in future clinical trials in order to clarify the exact mechanism of the beneficial effect of probiotics on AD and MCI patients.

Furthermore, a systematic review reveals that neither single nor multi-strain probiotics are beneficial for improving cognitive function according to eleven animal studies [26]. Many studies demonstrate that probiotics, such as Bifidobacterium and Lactobacillus strains, ameliorate cognitive and memory deficits in animal models of AD [50, 52, 53]. In the current study, the strains used in the involved clinical trials were also from Bifidobacterium and Lactobacillus (Table 3). We found that sole or multi-strain probiotics were both beneficial for improving cognitive function, suggesting that Bifidobacterium and Lactobacillus strains would be the most potential candidates. However, AD patients were insensitive to a mixture of six type of strains in the study from Azadeh Agahi et al. [29], indicating that the effectiveness of probiotics may be influenced by multifactors such as the severity of patients, proportion of each strains, dosage and so forth.

Table 3. Components of the probiotics in each RCTs.

Type of strainsElmira Akbari (2016)Omid Reza Tamtaji (2018)Azadeh Agahi (2018)Y. Kobayashi (2019)Yun-Ha Hwang (2019)
Bifidobacterium bifidum
Bifidobacterium breve A1
Bifidobacterium lactis
Bifidobacterium longum
Lactobacillus acidophilus
Lactobacilluscasei
Lactobacillus fermentum
Lactobacillus plantarum
Note: √ represents containing this type of strain in the component of probiotics.

Given the differences exist across species, the appropriate dosing of probiotics should be demonstrated for the specific target host [54]. The definition of probiotics requires the administration of an “adequate amount” in order to obtain a health benefit. However, the definition does not specify the size of this “adequate” dose [55, 56]. The commonly dose of probiotics used are ranging from 108 to 1011 CFU in related studies. Some researches [5759] appear to support a dose-response for probiotics in reducing the risk of antibiotic associated diarrhoea, suggesting that a dose greater than 1010 CFU is most effective. In contrast, there is no dose-response for probiotics in Clostridium difficile associated diarrhoea, necrotising enterocolitis, atopic dermatitis and slow intestinal transit [6067]. Compiled evidence indicates that the effective dose of probiotics is influenced by a multitude of variables, including health endpoint, the specific probiotic used, delivery vehicle and route of administration [68]. Therefore, it seems difficult to epitomize one optimal dose for probiotic intervention. At present, we failed to provide a dose-response of probiotics in ameliorating cognitive deficits for the information on the intervention dose of probiotics was not enough in the involved studies. Nevertheless, the absence of evidence for a dose-effect does not imply evidence of absence of a dose-effect [67]. More reliable evidence from various dosages especially outside the common concentration (108 ~ 1011 CFU) of probiotics trials is needed.

Additionally, the safety of probiotics should also be considered. People have been eating fermented foods for centuries without suffering any harmful side effects. Probiotics are generally accepted in the medical community as a harmless and very efficient, natural remedy. However, the United States Food and Drug Administration requires phase I safety studies for probiotics when the intended use of the product is as a drug. Researchers [69] have performed 108 to 1011 CFU/day doses of Bifidobacterium animalissubsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) in healthy young adults, and found that the increasing doses of probiotic bacteria were well tolerated and no volunteers reported adverse side effects during the intervention. Moreover, Patricia L. Hibberd et al. [70] reported that Lactobacillus rhamnosus GG ATCC 53103 (LGG)(1×1010 CFU), one of the most studied probiotic, is safe and well tolerated in healthy adults aged 65 years and older. Among the five studies included in our present study, two [28, 29] did not report on the incidence of side effects; two [27, 30] reported no side effects and only one [31] reported mild adverse events (e.g. stomach aches, headaches, gastritis, erectile dysfunction). These results indicate that probiotics are considered generally safe to consume, but may cause bacteria-host interactions and unwanted side effects in rare cases. Accordingly, the Bifidobacterium and Lactobacillus strains used in the involved studies were safe and well tolerated, however, the specific strain still need phase I safety studies before using as a drug.

The main limitations are as follows: 1) First, the cognitive rating scales varied across the recruited studies. The widely accepted cognitive rating scale, the MMSE, was selected in three studies [27, 28, 30], and one trial chose the Test Your Memory (TYM) test. Remarkably, AD patients assessed by the MMSE [27, 28] revealed a positive effect of the probiotics, while the TYM test in patients with AD found the opposite result. The main reason for this discrepancy may arise from the difference in the outcome indexes among studies; furthermore, the TYM test has been reported to be more sensitive in detecting dementia than the MMSE [71]. In addition, Yun-Ha Hwang et al. [31] assessed three cognitive domains combined using the verbal learning test (VLT), auditory continuous performance test (ACPT), and digit span test (DST). Cognitive domains of this combined one are incomprehensive enough compared to the MMSE or TYM. The subgroup analysis showed that cognitive rating scales, i.e., “MMSE versus non-MMSE”, could partly explain the source of heterogeneity, and the imbalanced assessment methods may have discounted the meta-analysis outcome. 2) Second, the inclusion criteria for AD patients were all in accordance with the NINCDS-ADRDA criteria. However, the criteria for recruiting MCI subjects were different: Y. Kobayashi et al. [30] discriminated MCI and normal individuals using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), while Yun-Ha Hwang et al. [31] diagnosed MCI according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). This may have generated low comparability of these two trials attributable to inconsistent inclusion criteria. 3) Third, three of the five clinical trials used in the cognitive meta-analysis are from the same region. Though the participants’ characteristics, intervention conditions, cognitive rating scales were varied from each other and the main findings were inconsistent. There is still concern that the relatively low heterogeneity might be partially attributed to the clinical trials from the same region. Additionally, two of the three studies also had concerns regarding allocation bias and evaluation bias. These limitations might discount the outcomes of our meta-analysis. 4) Fourth, some other key variables, including the age, sex, and BMI of the samples, specific strain of the flora, dosage of probiotics, and drug form, may have exerted an influence on the results, but the relevant information obtained on the results was limited in this study. Moreover, possible dose-response of probiotics in ameliorating cognitive deficits also should be further explored. 5) Last but not least, we concluded that the potential mechanism was partially related to the anti-inflammatory and anti-oxidative property of probiotics in only 12 weeks study duration. However, many clinical trials of AD drugs (i.e, β-amyloidantibody, β-secretase inhibitors, tau aggregation inhibitor), long-term interventions of several years have failed [7274]. The beneficial efficacy of probiotics for AD and MCI in only 12 weeks study duration might be attributed to multi-directional mechanism regulation, including alterations in the levels of certain neurotransmitters, increasing neuroprotective molecules, such as brain-derived neurotrophic factor, reduction of inflammation and so forth [21, 75, 76]. In addition, there might be existence of sponsor bias in part of the included studies. Therefore, longer study durations are needed to determine the overall net benefits of probiotics. With a view to the above limitations, future RCTs that control these confounding factors are needed to clarify the moderators of probiotics effects on cognition.

Conclusions

The meta-analysis indicated that probiotics consumption enhanced cognition in subjects with AD or MCI, possibly through decreasing the levels of inflammatory and oxidative biomarkers. However, the current RCT evidence is insufficient and limited, the results should be cautiously interpreted, and more reliable evidence from large-scale, long-period, randomized, controlled trials is needed.

Methods

Literature search

A literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The preliminary search was performed through the EMBASE, PubMed, Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL) electronic databases without time restrictions, up to June 10, 2019. A snowball search was manually carried out by searching reference lists from relevant published reviews and the retrieved papers. We searched the first-group-term (AD or MCI-related term) with “OR”. Then used the same way for the second-group-term (human-related term) search and the third-group-term (probiotic-related term) search, followed by combing the number of records generated from the three groups of search term with “AND”. The following terms were searched in “all fields” for each electronic database: (Alzheimer’s disease OR dementia OR mild cognitive impairment OR cognitive dysfunction OR cognitive defect OR cognition OR memory OR mental capacity) AND (adult OR human) AND (probiotic OR yeast OR yoghurt OR fermented product OR lactobacillus OR bifidobacterium OR fermented dairy product OR synbiotics OR cultured milk products). Articles were limited to randomized controlled trials (RCTs).

Study selection

Eligible studies had to meet the following criteria: (1) The study was an RCT and published in peer-reviewed journal in English; (2) Adult human participants who had a diagnosis of AD or MCI (aged over 18 y); (3) Significant difference in form, appearance, taste, and smell of probiotics and placebo should not occur at baseline; (4) Any validated measure of cognitive assessment was acceptable; (5) Continuous data of cognitive outcomes, inflammatory and oxidative biomarkers at baseline and post-intervention, or the change from baseline, and the number of participants at baseline and post-intervention were reported or could be calculated from the data reported in the article.

Studies were excluded if they met any one of the following criteria: (1) The publications were abstracts, reviews, conference papers, study protocols, cross-sectional studies, nonhuman (in vitro and animal) studies or papers that did not report on any outcome of interest; (2) No post-intervention or change from baseline on scale scores of cognition was reported, and these data could not be calculated based on the information in the article; (3) The study reported on a sample that overlapped the sample in another study. In this case, only the study with the larger sample size was included.

Articles were initially and independently screened for eligibility by two investigators based on titles and abstracts. Duplicate and irrelevant papers were excluded. For the relevant candidates, the full articles were retrieved, reviewed and the references of each document were checked to find out potential candidates. Disagreements were resolved by discussion between the two researchers, or with a third reviewer.

Data extraction

Data were extracted independently by two authors (H-Y.D, M-L.C), using a predetermined form in accordance with the guidance of the Cochrane Handbook for Systematic Reviews of Interventions. Parameters collected including basic information of the RCTs (first author, published year, and study design), characteristics of the participants (sample size, disease type, age, and sex ratio), intervention-related variables (type of strains, duration, and dosage), outcome assessments (cognitive outcomes, inflammatory and oxidative biomarkers) and the main findings of each included study. To perform the meta-analysis, the following data of outcome assessments were extracted: the mean change score along with the associated variance (standard deviation [SD] or standard error of the mean [SEM]). When change scores were not available, the scores (mean±SD or mean±SEM) and the number of participants at baseline and post-intervention were extracted.

Risk of bias assessment

All studies were independently assessed for risk of bias by two authors, with disagreements resolved by discussion to reach consensus. The tool of the Cochrane Handbook for Systematic Reviews of Interventions was used, which included criteria for the following six aspects: random sequence generation, allocation concealment, blindness of participants and personnel, blindness of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. The results of the risk of bias assessment were pooled into Revman 5.3, and a “summary of risk of bias assessment” table was generated.

Statistical analysis

The primary outcomes of this study were the standardized mean differences (SMDs) of change from baseline between probiotics and placebo group. The SMD was tested by a Z statistic, and a two-tailed P < 0.05 was regarded as statistically significant. The inter-study heterogeneity was examined by chi-square (χ2) statistics and I2 statistics. The heterogeneity among the different studies was considered high if P < 0.1 for the χ2 statistic or I2 > 50% [77]. SMDs were calculated by fixed-effects or random-effects models. A sensitivity analysis was conducted to test the reliability of the findings using the leave-one-out method, while publication bias was assessed by Egger's test and Begg's test. Subgroup analyses were performed to examine the possible source of heterogeneity within these studies, and the subtypes involved cognitive rating scales (Mini-Mental State Examination, MMSE, versus non-MMSE), type of disease (AD versus MCI) and strains of flora (multiple versus sole). The statistical analyses of forest plots, sensitivity analysis, Egger's test, and Begg's test were performed in STATA software (version 12; StataCorp), while Revman 5.3. was used to generate the summary of risk of bias assessment.

Abbreviations

AD: Alzheimer’s disease; MCI: mild cognitive impairment; GM: gut microbiota; MGB: microbiota-gut-brain axis; CNS: central nervous system; CENTRAL: Cochrane Central Register of Controlled Trials; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCTs: randomized controlled trials; SMD: standardized mean difference; CIs: confidence intervals; SD: standard deviation; SEM: standard error of the mean; MMSE: Mini-Mental State Examination; TYM: Test Your Memory; VLT: verbal learning test; ACPT: auditory continuous performance test; DST: digit span test; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA); RBANS: Repeatable Battery for the Assessment of Neuropsychological Status; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th edition; MDA: malondialdehyde; hs-CRP: high-sensitivity C-reactive protein; TAC: total anti-oxidant capacity; GSH: total glutathione; NO: nitric oxide; ROS: reactive oxygen species; BBB: blood-brain barrier.

Acknowledgements

We are particularly grateful to Dr. Gaoming Li of the Statistics Department, School of Military Preventive Medicine, Third Military Medical University (Army Medical University) for his critical review and valuable suggestions that greatly improved the quality of this manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding

This work was supported by the National Natural Science Foundation of China (Grant number: 81703268); National Postdoctoral Foundation of China (Grant number: 2019M663973); National Postdoctoral Program for Innovative Talents (Grant number: BX20180378); The Excellent Youth Foundation of the Third Military Medical University (2017).

References

  • 1. ADI. World Alzheimer Report 2018: The state of the art of dementia research: New frontiers. An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer's Disease International; 2018.
  • 2. Deng H, Mi MT. Resveratrol Attenuates Aβ25-35 Caused Neurotoxicity by Inducing Autophagy Through the TyrRS-PARP1-SIRT1 Signaling Pathway. Neurochem Res. 2016; 41:2367–79. https://doi.org/10.1007/s11064-016-1950-9 [PubMed]
  • 3. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, et al, and International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet. 2006; 367:1262–70. https://doi.org/10.1016/S0140-6736(06)68542-5 [PubMed]
  • 4. ADI. World Alzheimer Report 2019: Attitudes to dementia. London: Alzheimer's Disease International; 2019.
  • 5. Manayi A, Saeidnia S, Gohari AR, Abdollahi M. Methods for the discovery of new anti-aging products—targeted approaches. Expert Opin Drug Discov. 2014; 9:383–405. https://doi.org/10.1517/17460441.2014.885014 [PubMed]
  • 6. La Rosa F, Clerici M, Ratto D, Occhinegro A, Licito A, Romeo M, Iorio CD, Rossi P. The Gut-Brain Axis in Alzheimer's Disease and Omega-3. A Critical Overview of Clinical Trials. Nutrients. 2018; 10. https://doi.org/10.3390/nu10091267 [PubMed]
  • 7. Pistollato F, Sumalla Cano S, Elio I, Masias Vergara M, Giampieri F, Battino M. Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease. Nutr Rev. 2016; 74:624–34. https://doi.org/10.1093/nutrit/nuw023 [PubMed]
  • 8. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015; 125:926–38. https://doi.org/10.1172/JCI76304 [PubMed]
  • 9. Liang S, Wang T, Hu X, Luo J, Li W, Wu X, Duan Y, Jin F. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience. 2015; 310:561–77. https://doi.org/10.1016/j.neuroscience.2015.09.033 [PubMed]
  • 10. Jiang C, Li G, Huang P, Liu Z, Zhao B. The Gut Microbiota and Alzheimer's Disease. J Alzheimers Dis. 2017; 58:1–15. https://doi.org/10.3233/JAD-161141 [PubMed]
  • 11. Buford TW. (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease. Microbiome. 2017; 5:80. https://doi.org/10.1186/s40168-017-0296-0 [PubMed]
  • 12. Szablewski L. Human Gut Microbiota in Health and Alzheimer’s Disease. J Alzheimers Dis. 2018; 62:549–60. https://doi.org/10.3233/JAD-170908 [PubMed]
  • 13. Junges VM, Closs VE, Nogueira GM, Gottlieb MG. Crosstalk between Gut Microbiota and Central Nervous System: A Focus on Alzheimer’s Disease. Curr Alzheimer Res. 2018; 15:1179–90. https://doi.org/10.2174/1567205015666180904155908 [PubMed]
  • 14. Leblhuber F, Egger M, Schuetz B, Fuchs D. Commentary: effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2018; 10:54. https://doi.org/10.3389/fnagi.2018.00054 [PubMed]
  • 15. Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, Xie Z, Chu X, Yang J, Wang H, Chang S, Gong Y, Ruan L, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 2019; 29:787–803. https://doi.org/10.1038/s41422-019-0216-x [PubMed]
  • 16. Bostanciklioğlu M. The role of gut microbiota in pathogenesis of Alzheimer’s disease. J Appl Microbiol. 2019; 127:954–967. https://doi.org/10.1111/jam.14264 [PubMed]
  • 17. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB, Rey FE. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017; 7:13537. https://doi.org/10.1038/s41598-017-13601-y [PubMed]
  • 18. Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019; 47:529–42. https://doi.org/10.1016/j.ebiom.2019.08.032 [PubMed]
  • 19. Kim MS, Kim Y, Choi H, Kim W, Park S, Lee D, Kim DK, Kim HJ, Choi H, Hyun DW, Lee JY, Choi EY, Lee DS, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut. 2020; 69:283–94. https://doi.org/10.1136/gutjnl-2018-317431 [PubMed]
  • 20. Kowalski K, Mulak A. Brain-Gut-Microbiota Axis in Alzheimer’s Disease. J Neurogastroenterol Motil. 2019; 25:48–60. https://doi.org/10.5056/jnm18087 [PubMed]
  • 21. Cryan JF, O’Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020; 19:179–194. https://doi.org/10.1016/S1474-4422(19)30356-4 [PubMed]
  • 22. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016; 375:2369–79. https://doi.org/10.1056/NEJMra1600266 [PubMed]
  • 23. Chunchai T, Thunapong W, Yasom S, Wanchai K, Eaimworawuthikul S, Metzler G, Lungkaphin A, Pongchaidecha A, Sirilun S, Chaiyasut C, Pratchayasakul W, Thiennimitr P, Chattipakorn N, Chattipakorn SC. Decreased microglial activation through gut-brain axis by prebiotics, probiotics, or synbiotics effectively restored cognitive function in obese-insulin resistant rats. J Neuroinflammation. 2018; 15:11. https://doi.org/10.1186/s12974-018-1055-2 [PubMed]
  • 24. Wallace CJ, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2017; 16:14. https://doi.org/10.1186/s12991-017-0138-2 [PubMed]
  • 25. Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016; 167:915–32. https://doi.org/10.1016/j.cell.2016.10.027 [PubMed]
  • 26. Wang H, Lee IS, Braun C, Enck P. Effect of Probiotics on Central Nervous System Functions in Animals and Humans: A Systematic Review. J Neurogastroenterol Motil. 2016; 22:589–605. https://doi.org/10.5056/jnm16018 [PubMed]
  • 27. Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M. Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer’s Disease: A Randomized, Double-Blind and Controlled Trial. Front Aging Neurosci. 2016; 8:256. https://doi.org/10.3389/fnagi.2016.00256 [PubMed]
  • 28. Tamtaji OR, Heidari-Soureshjani R, Mirhosseini N, Kouchaki E, Bahmani F, Aghadavod E, Tajabadi-Ebrahimi M, Asemi Z. Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer’s disease: A randomized, double-blind, controlled trial. Clin Nutr. 2019; 38:2569–75. https://doi.org/10.1016/j.clnu.2018.11.034 [PubMed]
  • 29. Agahi A, Hamidi GA, Daneshvar R, Hamdieh M, Soheili M, Alinaghipour A, Esmaeili Taba SM, Salami M. Does Severity of Alzheimer’s Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial. Front Neurol. 2018; 9:662. https://doi.org/10.3389/fneur.2018.00662 [PubMed]
  • 30. Kobayashi Y, Kuhara T, Oki M, Xiao JZ. Effects of Bifidobacterium breve A1 on the cognitive function of older adults with memory complaints: a randomised, double-blind, placebo-controlled trial. Benef Microbes. 2019; 10:511–20. https://doi.org/10.3920/BM2018.0170 [PubMed]
  • 31. Hwang YH, Park S, Paik JW, Chae SW, Kim DH, Jeong DG, Ha E, Kim M, Hong G, Park SH, Jung SJ, Lee SM, Na KH, et al. Efficacy and Safety of Lactobacillus Plantarum C29-Fermented Soybean (DW2009) in Individuals with Mild Cognitive Impairment: A 12-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2019; 11:E305. https://doi.org/10.3390/nu11020305 [PubMed]
  • 32. Cheng LH, Liu YW, Wu CC, Wang S, Tsai YC. Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders. Yao Wu Shi Pin Fen Xi. 2019; 27:632–48. https://doi.org/10.1016/j.jfda.2019.01.002 [PubMed]
  • 33. Morris MC, Tangney CC, Wang Y, Sacks FM, Barnes LL, Bennett DA, Aggarwal NT. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015; 11:1015–22. https://doi.org/10.1016/j.jalz.2015.04.011 [PubMed]
  • 34. Alkasir R, Li J, Li X, Jin M, Zhu B. Human gut microbiota: the links with dementia development. Protein Cell. 2017; 8:90–102. https://doi.org/10.1007/s13238-016-0338-6 [PubMed]
  • 35. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des. 2010; 16:2766–78. https://doi.org/10.2174/138161210793176572 [PubMed]
  • 36. Downey LA, Simpson T, Timmer J, Nolidin K, Croft K, Wesnes KA, Scholey A, Deleuil S, Stough C. Impaired verbal episodic memory in healthy older adults is marked by increased F2-Isoprostanes. Prostaglandins Leukot Essent Fatty Acids. 2018; 129:32–37. https://doi.org/10.1016/j.plefa.2018.02.001 [PubMed]
  • 37. Selvarajah D, Wilkinson ID, Davies J, Gandhi R, Tesfaye S. Central nervous system involvement in diabetic neuropathy. Curr Diab Rep. 2011; 11:310–22. https://doi.org/10.1007/s11892-011-0205-z [PubMed]
  • 38. Sultana R, Mecocci P, Mangialasche F, Cecchetti R, Baglioni M, Butterfield DA. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer’s disease: insights into the role of oxidative stress in Alzheimer’s disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis. 2011; 24:77–84. https://doi.org/10.3233/JAD-2011-101425 [PubMed]
  • 39. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010; 362:329–44. https://doi.org/10.1056/NEJMra0909142 [PubMed]
  • 40. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA. Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer’s disease. Neurodegener Dis. 2010; 7:38–41. https://doi.org/10.1159/000283480 [PubMed]
  • 41. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006; 12:1005–15. https://doi.org/10.1038/nm1484 [PubMed]
  • 42. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis. 2010; 19:355–61. https://doi.org/10.3233/JAD-2010-1219 [PubMed]
  • 43. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol. 2003; 27:325–55. https://doi.org/10.1385/MN:27:3:325 [PubMed]
  • 44. Crouch PJ, Barnham KJ, Duce JA, Blake RE, Masters CL, Trounce IA. Copper-dependent inhibition of cytochrome c oxidase by Abeta(1-42) requires reduced methionine at residue 35 of the Abeta peptide. J Neurochem. 2006; 99:226–36. https://doi.org/10.1111/j.1471-4159.2006.04050.x [PubMed]
  • 45. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006; 15:1437–49. https://doi.org/10.1093/hmg/ddl066 [PubMed]
  • 46. Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer’s disease. J Neuroinflammation. 2006; 3:30. https://doi.org/10.1186/1742-2094-3-30 [PubMed]
  • 47. Matos M, Augusto E, Oliveira CR, Agostinho P. Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience. 2008; 156:898–910. https://doi.org/10.1016/j.neuroscience.2008.08.022 [PubMed]
  • 48. Clark A, Mach N. The Crosstalk between the Gut Microbiota and Mitochondria during Exercise. Front Physiol. 2017; 8:319. https://doi.org/10.3389/fphys.2017.00319 [PubMed]
  • 49. D’Souza A, Fordjour L, Ahmad A, Cai C, Kumar D, Valencia G, Aranda JV, Beharry KD. Effects of probiotics, prebiotics, and synbiotics on messenger RNA expression of caveolin-1, NOS, and genes regulating oxidative stress in the terminal ileum of formula-fed neonatal rats. Pediatr Res. 2010; 67:526–31. https://doi.org/10.1203/PDR.0b013e3181d4ff2b [PubMed]
  • 50. Athari Nik Azm S, Djazayeri A, Safa M, Azami K, Ahmadvand B, Sabbaghziarani F, Sharifzadeh M, Vafa M. Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1-42) injected rats. Appl Physiol Nutr Metab. 2018; 43:718–26. https://doi.org/10.1139/apnm-2017-0648 [PubMed]
  • 51. Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, Yasuoka A, Kondo T, Abe K, Xiao JZ. Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease. Sci Rep. 2017; 7:13510. https://doi.org/10.1038/s41598-017-13368-2 [PubMed]
  • 52. Nimgampalle M, Kuna Y. Anti-Alzheimer Properties of Probiotic, Lactobacillus plantarum MTCC 1325 in Alzheimer’s Disease induced Albino Rats. J Clin Diagn Res. 2017; 11:KC01–05. https://doi.org/10.7860/JCDR/2017/26106.10428 [PubMed]
  • 53. Musa NH, Mani V, Lim SM, Vidyadaran S, Abdul Majeed AB, Ramasamy K. Lactobacilli-fermented cow’s milk attenuated lipopolysaccharide-induced neuroinflammation and memory impairment in vitro and in vivo. J Dairy Res. 2017; 84:488–95. https://doi.org/10.1017/S0022029917000620 [PubMed]
  • 54. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017; 14:491–502. https://doi.org/10.1038/nrgastro.2017.75 [PubMed]
  • 55. FAO/WHO. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO working group on drafting guidelines for the evaluation of probioticsin food. FAO/WHO; 2002.
  • 56. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11:506–14. https://doi.org/10.1038/nrgastro.2014.66 [PubMed]
  • 57. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006; 101:812–22. https://doi.org/10.1111/j.1572-0241.2006.00465.x [PubMed]
  • 58. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002; 109:678–84. https://doi.org/10.1542/peds.109.4.678 [PubMed]
  • 59. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011; CD004827. https://doi.org/10.1002/14651858.CD004827.pub3 [PubMed]
  • 60. Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, Guyatt GH, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013; CD006095. https://doi.org/10.1002/14651858.CD006095.pub3 [PubMed]
  • 61. McFarland LV. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Antibiotics (Basel). 2015; 4:160–78. https://doi.org/10.3390/antibiotics4020160 [PubMed]
  • 62. Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016; 9:27–37. https://doi.org/10.2147/IJGM.S98280 [PubMed]
  • 63. Aceti A, Gori D, Barone G, Callegari ML, Di Mauro A, Fantini MP, Indrio F, Maggio L, Meneghin F, Morelli L, Zuccotti G, Corvaglia L, and Italian Society of Neonatology. Probiotics for prevention of necrotizing enterocolitis in preterm infants: systematic review and meta-analysis. Ital J Pediatr. 2015; 41:89. https://doi.org/10.1186/s13052-015-0199-2 [PubMed]
  • 64. Pelucchi C, Chatenoud L, Turati F, Galeone C, Moja L, Bach JF, La Vecchia C. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012; 23:402–14. https://doi.org/10.1097/EDE.0b013e31824d5da2 [PubMed]
  • 65. Zhang GQ, Hu HJ, Liu CY, Zhang Q, Shakya S, Li ZY. Probiotics for Prevention of Atopy and Food Hypersensitivity in Early Childhood: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2016; 95:e2562. https://doi.org/10.1097/MD.0000000000002562 [PubMed]
  • 66. Miller LE, Zimmermann AK, Ouwehand AC. Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit. World J Gastroenterol. 2016; 22:5122–31. https://doi.org/10.3748/wjg.v22.i21.5122 [PubMed]
  • 67. Ouwehand AC. A review of dose-responses of probiotics in human studies. Benef Microbes. 2017; 8:143–51. https://doi.org/10.3920/BM2016.0140 [PubMed]
  • 68. Sanders ME, Merenstein D, Merrifield CA, Hutkins R. Hutkins. Probiotics for human use. Nutr Bull. 2018; 43:212–25. https://doi.org/10.1111/nbu.12334
  • 69. Larsen CN, Nielsen S, Kaestel P, Brockmann E, Bennedsen M, Christensen HR, Eskesen DC, Jacobsen BL, Michaelsen KF. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr. 2006; 60:1284–93. https://doi.org/10.1038/sj.ejcn.1602450 [PubMed]
  • 70. Hibberd PL, Kleimola L, Fiorino AM, Botelho C, Haverkamp M, Andreyeva I, Poutsiaka D, Fraser C, Solano-Aguilar G, Snydman DR. No evidence of harms of probiotic Lactobacillus rhamnosus GG ATCC 53103 in healthy elderly-a phase I open label study to assess safety, tolerability and cytokine responses. PLoS One. 2014; 9:e113456. https://doi.org/10.1371/journal.pone.0113456 [PubMed]
  • 71. van de Zande E, van de Nes JC, Jansen I, van den Berg MN, Zwart AF, Bimmel D, Rijkers GT, Andringa G. The Test Your Memory (TYM) Test Outperforms the MMSE in the Detection of MCI and Dementia. Curr Alzheimer Res. 2017; 14:598–607. https://doi.org/10.2174/1567205013666161201202520 [PubMed]
  • 72. Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014; 10:405–19. https://doi.org/10.1586/1744666X.2014.883921 [PubMed]
  • 73. Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease. BioMed Res Int. 2016; 2016:3245935. https://doi.org/10.1155/2016/3245935 [PubMed]
  • 74. Gautam RRG. Pipeline assessment of beta-secretase inhibitors for alzheimer’s disease: hopes or gloom for a trillion dollar market. Value Health. 2017; 20:A887. https://doi.org/10.1016/j.jval.2017.08.2654
  • 75. Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am. 2017; 46:77–89. https://doi.org/10.1016/j.gtc.2016.09.007 [PubMed]
  • 76. Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflammation. 2019; 16:108. https://doi.org/10.1186/s12974-019-1494-4 [PubMed]
  • 77. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. 2013.